Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline ...
Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading ...
On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...
Astex Pharmaceuticals, Bristol Myers Squibb and Takeda have agreed to pool data to support work on an artificial intelligence model, joining AbbVie and Johnson & Johnson on the starry list of ...
On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...
Monitoring and managing Li-ion batteries is key for extending runtime and minimizing risks like thermal runaway. Test your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback